This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

OPAL Broaden & Beyond
​​​​​​​- PsA Efficacy Results

XELJANZ delivers rapid and sustained improvements in joint symptoms vs placebo as measured by ACR201,2

Adapted from Mease P et al. 2017.2

In addition, significant ACR50 and ACR70 responses were achieved at Month 31

ACR50: 28% vs 10% in the XELJANZ and placebo group, respectively (p<0.001)1
ACR70: 17% vs 5% in the XELJANZ and placebo group, respectively (p=0.004)1

Statistical testing was performed comparing placebo with XELJANZ up to three months.
​​​​​​​* Co-primary endpoints were the proportion of patients who had an ACR20 response at month 3 and the change from baseline in HAQ-DI score at Month 3.
 The OPAL Broaden study was designed to test for superiority of XELJANZ over placebo. Adalimumab was used as an active control. The trial was not designed and was not powered to evaluate the non-inferiority or superiority of XELJANZ as compared with adalimumab.
 Statistically significant vs placebo at a p≤0.05 as per the prespecified step-down procedure for type I error control within the ACR20 time course.1
§ The result was significant at a p≤0.05 according to the prespecified step-down testing procedure for type I error control within the family of ACR responses.1

Adapted from Gladman D et al. 2017.4

In addition, a significant ACR50 response was achieved at Month 3 with XELJANZ**3

An ACR50 response was achieved in 29.8% of patients on XELJANZ 5 mg vs 14.5% of patients on placebo (p=0.0025)3,4​​​​​

*  Co-primary endpoints were the proportion of patients who had an ACR20 response at month 3 and the change from baseline in HAQ-DI score at Month 3
 Statistically significant vs placebo at a p≤0.05 as per the prespecified step-down procedure for type I error control within the ACR20 time course.3
** The result was significant at a p value of ≤0.05 according to the prespecified step-down testing procedure for type I error control within the family of ACR responses.3
†† Statistically significant vs placebo at a p≤0.05 as per the prespecified step-down procedure for global type I error control.3

Adapted from Mease P et al. 2017 (supplementary appendix).2

Radiographic non-progression was observed in the majority of patients across all trial groups at 12 months (96% for XELJANZ, 98% for adalimumab and 96% for placebo to XELJANZ, respectively)1,2

*​​​​​​​** The OPAL Broaden study was designed to test for superiority of XELJANZ over placebo. Adalimumab was used as an active control. The trial was not designed and was not powered to evaluate the non-inferiority or superiority of XELJANZ as compared with adalimumab.
‡‡ Radiographs of the hands and feet were obtained at baseline and at Month 12 and were scored independently by two central assessors who were unaware of the trial-group assignments.

Explore more


Header

References

  1. Item


Explore More

Dosing in PsA

Visit page


ACR=American College of Rheumatology; BID=twice-daily; csDMARD=conventional synthetic disease-modifying antirheumatic drug; HAQ-DI=Health Assessment Questionnaire-Disability Index; IR=inadequate responder; mTSS=modified Total Sharp Score; PsA=psoriatic arthritis; Q2W=once every two weeks; SC=subcutaneous; TNFi=tumour necrosis factor inhibitor.

Prescribing Information:
​​​​​​​

Xeljanz (tofacitinib citrate) Prescribing Information (Great Britain) - 5mg film-coated tablets
Xeljanz (tofacitinib citrate) Prescribing Information (Northern Ireland) -  5mg and 10mg film-coated tablets
​​​​​​​​​​
References:
​​​​​​​
  1. Mease P et al. N Engl J Med 2017; 377: 1537–1550
  2. Mease P et al. N Engl J Med 2017; 377: 1537–1550 (supplementary appendix)
  3. Gladman D et al. N Engl J Med 2017; 377: 1525–1536
  4. ​​​​​​​Gladman D et al. N Engl J Med 2017; 377: 1525–1536 (supplementary appendix)
PP-XEL-GBR-3251. October 2021

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

PsA Clinical Efficacy

OPAL Broaden & Beyond

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No